Kommentar zu „SINUS-52-Studie: Subgruppenanalyse japanischer Patient*innen"

• Literatur

• 1 Bachert C, Han JK, Desrosiers M. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; et al. 394: 1638-1650
• 2 Wang X, Zhang N, Bo M. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol 2016; et al. 138: 1344-1353
• 3 Bachert C, Han JK, Wagenmann M. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol 2021; et al. 147: 29-36